ArticleTranslational vision science & technology2025
Presbyopia Progression From the Age of 40 to 79 Years in Glaucoma Patients Treated With Prostaglandin F Receptor Agonists.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reduced Accommodation Without Mydriasis After Micropulse Cyclophotocoagulation in a Young Congenital Glaucoma Patient: A Case Report.The American journal of case reports · 2026Article
- Presbyopic Glaucoma Patients Exhibit Greater Contact Lens Under-Correction Than Non-Glaucomatous Subjects.Clinical optometry · 2026Article
- Sex Differences in Preferred Under-Correction of Contact Lenses and Their Potential Relevance to Presbyopia Management.Clinical optometry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to compare the near add power of glaucoma patients and controls between the ages of 40 and 79 years. Methods: This was a cross-sectional study of 2724 bilateral phakic participants aged between 40 and 79 years, which included 1615 controls and 1109 patients with primary open-angle glaucoma who were using prostaglandin F (FP) receptor agonists. Participants were classified into eight age groups: 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75-79 years of age. We compared the near add power and other ocular parameters between glaucoma patients and controls by age group. Results: There was a significant difference between glaucoma patients and controls and in spherical equivalent, intraocular pressure, cup/disc ratio, ganglion cell complex thickness, peripapillary retinal nerve fiber layer thickness, and use of dry eye eyedrops across all or many of the age groups studied. The near add power of glaucoma patients was comparable to controls of the immediately older age group until 65-69 years, indicating that the advancement of near add power of glaucoma patients was approximately five years earlier than in controls until that age range. Conclusions: There was an earlier progression of presbyopia determined by near add power in glaucoma patients treated with FP receptor agonists compared with controls. Translational Relevance: Between ages 40 and 79 years, glaucoma patients treated with prostaglandin F receptor agonists had higher near add power than controls. This knowledge could contribute to informing better management of glaucoma patients with presbyopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.